Takeda Pharmaceutical Company Limited (4502.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

40.5x

EV/EBITDA

10.9x

Market Cap

JPY 9.33T

MomentumView details →

1D Return

+1.44%

YTD Return

+18.99%

RSI (14)

53.5

ValuationView details →

P/E (Fwd)

40.5x

EV/EBITDA

10.9x

Market Cap

JPY 9.33T

RSI (14)

53.5

MomentumView details →

1D Return

+1.44%

YTD Return

+18.99%

ProfitabilityView details →

Gross Margin

65.12%

Net Margin

4.26%

EBITDA Margin

25.08%

ROE (TTM)

2.47%

ROA (TTM)

1.24%

Asset Turnover

0.29x

GrowthView details →

Revenue YoY

−1.66%

EPS YoY

+77.64%

FCF YoY

+1.06%

Revenue CAGR 3Y

+3.81%

EPS CAGR 3Y

−15.85%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.63x

Current Ratio

1.27x

Quick Ratio

0.70x

Div Yield

3.39%

Div Rate

JPY 200.00

Div Growth 1Y

+2.04%

Financials snapshotView financials →

Revenue (TTM)

4.51T

Net Income (TTM)

191.76B

Op. CF (TTM)

1.04T

Next earningsOct 29, 2026 →

Latest newsMore news →

Daiichi Sankyo's market capitalization fell about 55% from its peak in July 2024 to 5.3707 trillion yen as of September 2, 2026, dropping it to fourth place among Japanese pharmaceutical companies.2d ago

The U.S. Food and Drug Administration approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer, announced on Friday.7d ago

Similar companies

CHUGAI PHARMACEUTICAL CO.,LTD.4519.T Otsuka Holdings Co.,Ltd.4578.T DAIICHI SANKYO COMPANY,LIMITED4568.T Astellas Pharma Inc.4503.T Shionogi & Co.,Ltd.4507.T Eisai Co.,Ltd.4523.T Find similar companies →

Latest newsMore news →

Daiichi Sankyo's market capitalization fell about 55% from its peak in July 2024 to 5.3707 trillion yen as of September 2, 2026, dropping it to fourth place among Japanese pharmaceutical companies.2d ago The U.S. Food and Drug Administration approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer, announced on Friday.7d ago